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Abstract There is a growing appreciation for the adverse
long-term impact of right-sided valvular dysfunction in pa-
tients with congenital heart disease. Although right-sided val-
vular stenosis and/or regurgitation is often better tolerated than
left-sided valvular dysfunction in the short and intermediate
term, the long-term consequences are numerous and include,
but are not limited to, arrhythmias, heart failure, and multi-
organ dysfunction. Surgical right-sided valve interventions
have been performed for many decades, but the comorbidities
associated with multiple surgeries are a concern. Transcatheter
right-sided valve replacement is safe and effective and is being
performed at an increasing number of centers around the
world. It offers an alternative to traditional surgical techniques
and may potentially alter the decision making process where-
by valvular replacement is performed prior to the development
of long-term sequelae of right-sided valvular dysfunction.
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Introduction
The progress of congenital heart disease (CHD) surgical inter-
ventions over the past few decades has allowed more children
to survive well into adulthood. Most of these patients will
require multiple surgical procedures over their lifetime. This
can be associated with increased morbidity and mortality [1,
2] due to chest adhesions, bleeding, cardiac ischemia, arrhyth-
mia burden, heart failure, and multi-organ dysfunction [3–7].
Since the introduction of the first balloon expandable valve in
the pulmonary position by Bonhoeffer et al [8] in 2000, ad-
vances in interventional cardiology and percutaneous valve
replacement have revolutionized the management of these pa-
tients. The availability of these minimally invasive and effec-
tive therapies may allow for earlier treatment of right-sided
valvular disease before the onset of irreversible ventricular
remodeling and dysfunction. Moreover, transcatheter options
can reduce the need for multiple surgical interventions over a
patient’s lifetime, therefore affecting the morbidity of this
growing patient population [9]. We herein discuss the impact
of existing and future catheter-based valve implantation tech-
niques for dysfunctional right-sided valves.
Pathophysiology and Clinical Presentation
of Right-sided Valvular Dysfunction in Congenital
Heart Disease
Pulmonary Valve
Pulmonary valve disease in the congenital population can be
native or post-operative. Native pulmonary valve dysfunction
may be isolated, as in congenital pulmonary stenosis, or may
be a part of a recognized condition such as tetralogy of Fallot.
Surgical valve or conduit placement is often not performed in
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infancy or early childhood in preference to procedures that
alleviate pulmonic stenosis such as pulmonary valvotomy
and subannular or transannular patch placement. These tech-
niques invariably leave the patient with chronic severe pulmo-
nary regurgitation. Surgical pulmonary valve interventions
usually consist of valve replacement with either bioprosthetic
valves or valved conduits. Rarely, patients may undergo me-
chanical pulmonic valve replacement. Bioprosthetic valves
and conduits (usually homografts) invariably develop pro-
gressive dysfunction within 10–20 years of implantation with
resultant stenosis and/or regurgitation [10–12].
Although pulmonary valve dysfunction is generally well
tolerated, patients often develop progressive exertional limita-
tions and may develop ventricular and supraventricular ar-
rhythmias. Decompensated congestive heart failure is a late
manifestation that usually occurs well after the development
of exertional symptoms. In patients with progressive stenosis,
right ventricular hypertrophy develops as a compensatory
mechanism for the increased pressure with resultant right ven-
tricular diastolic dysfunction and eventually systolic dysfunc-
tion ensues [13]. Severe chronic pulmonary regurgitation re-
sults in right ventricular volume overload which leads to ven-
tricular dilatation, progressive systolic and diastolic dysfunc-
tion, and tricuspid regurgitation due to annular dilatation [14].
Ventricular and atrial arrhythmias are likely to occur in pa-
tients with both stenosis and regurgitation and result in an
increased risk of sudden death in this population [7, 15].
The timing of pulmonary valve replacement in these pa-
tients is controversial [16, 17]. Several studies have evaluated
the timing of pulmonary valve replacement in patients with
severe chronic pulmonary regurgitation and have suggested
that normalization of right ventricular volume will not occur
in patients with severely dilated right ventricles (right ventric-
ular end-diastolic volume (RVEDV) >150 ml/m2 or right ven-
tricular end-systolic volume (RVESV) >80 ml/m2) [18–23].
Therefore, it is generally recommended that patients undergo
pulmonary valve replacement prior to severe right ventricular
dilation or systolic dysfunction. However, there is little evi-
dence that such an approach results in improved clinical out-
comes, such as reduced arrhythmia burden or decreased mor-
tality. Furthermore, it is not clear that different etiologies of
pulmonic regurgitation behave in the same pathophysiological
manner, and thus thresholds developed for regurgitation fol-
lowing repair of tetralogy of Fallot may not apply to those
patients with initial isolated pulmonic stenosis [24]. It does
appear likely that earlier PVR results in improved exercise
tolerance, especially in patients with predominant pulmonary
stenosis [17, 25].
Tricuspid Valve
Native tricuspid valve dysfunction in patients with congenital
heart disease is often associated with Ebstein anomaly, which
mayresult inchronicsevere tricuspid regurgitation.Severe tricus-
pid regurgitation is often well tolerated for decades. However,
much like pulmonic regurgitation, eventual clinical sequelaewill
emerge. These include the development of ventricular and supra-
ventricular arrhythmias, elevated central venous pressure with
resultant multi-organ congestion (congestive hepatopathy, renal
dysfunction, splenomegaly), and progressive right ventricular
dysfunction. Native tricuspid valve regurgitation may occur as a
result of progressive right ventricular and tricuspid annular dila-
tion or in patientswith severely elevated right ventricular systolic
pressure due to severe pulmonary hypertension or right ventricu-
lar outflowobstruction. Therefore, it is common for patientswith
RVOTdysfunction, as in repaired tetralogy of Fallot or pulmonic
stenosis, to develop secondary tricuspid regurgitation. Surgical
techniques for tricuspid valve repair include the placement of
annular bands or rings as well as more complex operations to
relocate or augment the tricuspid valve leaflets (as in Ebstein’s).
Progressive tricuspid regurgitation is common during long-term
follow-up of these patients and manifests in a similar clinical
manner tonative tricuspid regurgitation. If surgical valve replace-
ment is warranted, bioprosthetic valves are preferred, although
there is limited data on the safety and efficacy of mechanical
prostheses. Bioprosthetic tricuspid valves can become dysfunc-
tional over time and generally require replacement within a de-
cade. Progressive regurgitation and/or stenosis may occur with
the clinical sequelae of elevated central venous pressure and re-
duced cardiac output [26, 27].
Diagnostic Methods of Right-Sided Valvular Disease
in Congenital Heart Disease
Echocardiography
Echocardiography is a widely available and cost-effective tool
for the assessment of congenital cardiac structure and func-
tion. It is universally utilized for the diagnosis of stenotic or
regurgitant valvular lesions using qualitative measures such as
color Doppler (Fig. 1), and density and contour of regurgitant
signals, as well as quantitative measures such as vena
contracta, effective regurgitant orifice area, and velocity of
flow. The echocardiographic exam for right-sided heart le-
sions also includes assessment of right and left ventricular size
and function, right ventricular outflow tract (RVOT) and tri-
cuspid annular dimensions, pulmonary arterial pressure, right
and left atrial filling pressures, and systemic and pulmonary
blood flow [28–31]. The addition of 3D echo imaging facili-
tates the quantitative assessment of right ventricular volume
and ejection fraction. The use of tissue Doppler and speckle
tracking for assessment of systolic and diastolic function, in-
cluding regional and global right ventricular strain, is an area
of growing interest [32]. Echocardiography typically provides
excellent visualization of the tricuspid valve but is less optimal
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for imaging the pulmonic valve, especially in adult patients.
Moreover, echocardiography is widely utilized for the assess-
ment of prosthetic valve function. The comprehensive use of a
non-invasive and cost-effective tool such as echocardiography
has obviated the need for diagnostic invasive catheterization
in most patients with congenital heart disease.
Computed Tomography Angiography
Cardiac tomography angiography (CTA) has become an inte-
gral part of the evaluation of patients with aortic valve disease
prior to transcatheter aortic valve replacement (TAVR). CTA
is not as widely utilized for the evaluation of patients with
congenital heart disease, as many centers prefer to use cardiac
MRI due to concerns over radiation and its limitations in func-
tional assessment due to the lack of blood velocity measure-
ments. Also, CTA requires the injection of iodinated contrast,
which is nephrotoxic, and therefore the use of this modality is
limited in patients with advanced renal dysfunction. However,
ECG-gated chest CTA can provide excellent spatial and tem-
poral resolution and is extremely useful in the assessment of
right ventricular outflow tract abnormalities, both native and
post-operative [33]. Moreover, CTA allows for visualization
of the coronary arterial anatomy and its relationship to the
right ventricular outflow tract and pulmonary artery.
Therefore, CTA can be a useful tool for procedural planning
in patients with congenital valvular heart disease [34]. The
advent of 3D printing from cross-sectional imaging data al-
lows for individualized planning of complex structural inter-
ventions [35].
Cardiac Magnetic Resonance Imaging
Cardiac Magnetic Resonance Imaging (CMR) is widely used
for the assessment of congenital heart disease, as it provides
anatomic data as well as qualitative and quantitative measure-
ments of valvular regurgitation and/or stenosis. In addition, it
provides accurate ventricular dimensions and function. CMR
is especially useful for measuring pulmonary regurgitant vol-
ume and right ventricular volumes, which are critical param-
eters for determining the optimal timing for intervening on
pulmonary valve regurgitation [36–39]. CMR is non-
invasive and does not expose patients to radiation; however,
it is time consuming, not universally available, and more ex-
pensive than echocardiography and is contraindicated in some
patients with pacemakers and defibrillators.
Cardiac Catheterization and Invasive Angiography
Diagnostic cardiac catheterization was once utilized universal-
ly in patients with congenital heart disease but has been
supplanted over the past 30 years by the aforementioned
non-invasive imaging tools. In cases where the non-invasive
data is inconclusive or contradictory, diagnostic catheteriza-
tion may be necessary. In patients with right-sided congenital
valvular disease, catheterization provides direct pressure mea-
surements, facilitates angiography, and allows for accurate
measurement of shunts. Moreover, in patients with pulmonary
hypertension, catheterization allows for the calculation of pul-
monary arterial resistance and determination of pulmonary
vasoreactivity. Additionally, invasive hemodynamic assess-
ment during steady state alterations, such as volume loading,
stress testing, or infusion of inotropic medications can provide
valuable information. That being said, the majority of patients
today undergo invasive catheterization mainly for interven-
tional purposes; however, the hemodynamic data gathered
pre- and post-intervention is integral to their management.
Catheter-Based Therapies
Indications for intervention are often based on symp-
tomatology, severity of the stenosis or regurgitation,
right ventricular volume and function, and the burden
of arrhythmias [22, 38, 40].
Fig. 1 a Transthoracic echocardiographic image (parasternal short axis
view) of the right ventricular outflow tract (RVOT) showing turbulent
color Doppler flow across a stenotic pulmonary valve. AV = aortic
valve. b Parasternal short axis view of RVOT with an indwelling stent
in the main pulmonary artery well above the level of the pulmonary valve
annulus and color Doppler flow showing severe pulmonary valve
regurgitation (PR). Note the regurgitant reverse color Doppler flow in
the left pulmonary artery (LPA) and right pulmonary artery (RPA). c
Parasternal short axis view of the RVOT showing a Melody valve
successfully deployed in the MPA
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Pulmonary Valve
Transcatheter pulmonary valve (TCPV) replacement can alle-
viate RVOT conduit dysfunction whether due to stenosis, re-
gurgitation, or both, thereby delaying the need for open heart
surgery and essentially decreasing the number of operations
with their associated morbidities [41, 42]. The Melody
(Medtronic) TCPV was the first valve to receive FDA approv-
al, initially under humanitarian device exemption in 2010 and
thereafter for clinical use in 2014. TheMelody valve is widely
used for the treatment of dysfunctional right ventricular to
pulmonary artery (RV-PA) conduits and bioprosthetic valves
and more recently has been used to treat dysfunctional native
RVOT lesions (Figs. 2 and 3). Due to the size of the deploy-
ment system (22 Fr), when used via a transvenous approach, it
is restricted to patients weighing more than 20–30 kg [41, 43].
This limitation does not apply when a hybrid surgical ap-
proach is utilized. Currently, the first generation Sapien
(Edwards Lifesciences) TCPV is under investigation, also
with a 22- and 24-F system (COMPASSION Clinical Trial
NCT00676689). The later generations of the Sapien valve
(Sapien XT and Sapien 3) are FDA-approved for use in the
aortic position and are being used by multiple centers for off-
label implantation in the pulmonary position (Fig. 4). The
larger-diameter Sapien valves (26 and 29 mm) allow for im-
plantation in large dysfunctional native RVOTs. The Sapien
XT is also under clinical investigation currently for the pul-
monary position (COMPASSION III Clinical Trial
NCT02302131).
Short-term outcomes of the Melody valve have proven the
durability of the valve [44–50]. Furthermore, there is signifi-
cant hemodynamic and clinical improvements after Melody
valve placement due to right ventricular remodeling, decrease
in end diastolic volumes, increase in cardiac output, and sub-
sequently an improvement in exercise tolerance [17, 25, 44,
48, 49, 51–54, 55•]. This effect is seen more significantly in
patients with RVOT obstruction and/or regurgitation versus
those with only regurgitant lesions [25]. Favorable longer-
term outcomeswere seen after a median follow-up of 4.5 years
in 148 patients in the US melody valve investigational device
exemption trial, with a 5-year freedom from re-intervention of
76 % and a 5-year freedom from explant of 92 % [56].
Stent fracture and endocarditis have been the primary
causes for re-intervention [47, 55•, 57, 58, 59•]. Stent fracture
often occurs in patients with conduits or native RVOT dys-
function and is likely due to repetitive stress on the platinum
iridium frame. Pre-stenting before Melody valve placement
has significantly reduced the incidence of stent fracture.
Also, valve-in-valve implantation is a successful treatment
option for Melody valve stent fracture (Fig. 5) [47, 55•,
60–62]. As for endocarditis, adherence with SBE prophylaxis
is imperative; however, data suggests there is an increased risk
of infective endocarditis with implanted Melody valves [57,
58, 59•]. Other complications such as conduit or pulmonary
artery dissection or rupture are life threatening but rare and can
be treated with covered stent placement. There is a 5 % risk of
coronary artery compression, but this risk can be reduced by
performing simultaneous balloon inflation in the RVOT with
coronary or aortic root angiography to test for coronary artery
compression (Fig. 6) [63]. Aortic compression may also occur
in this population (Fig. 7). Lastly, valve embolization is a rare
risk; which can be averted by adequate pre-procedural plan-
ning and RVOT sizing. However, when it does occur and the
valve cannot be safely deployed in a distal pulmonary artery
branch or vena cava, surgical removal may be necessary.
Transcatheter pulmonary valve replacement has also been
successfully performed within failed bioprosthetic valves, not
as part of RV-PA conduits, with excellent outcomes including
freedom from repeat intervention of 92 % at 1 year and 92 %
at 2 years [64]. TheMelody valve can be utilized in most large
diameter bioprostheses, up to a 24-mmmaximal diameter, and
the 26- or 29-mm Sapien valves can be used as well if the
diameter is too large for a Melody valve [65].
In the subset of congenital heart disease patients with native
RVOT or RVOT patch repairs, there is a growing body of
literature on the utility of commercially available valves used
off-label. In a retrospective trial of 31 patients, Melody pul-
monary valve implantation in native RVOT due to either ste-
nosis or regurgitation was safe and feasible; however, there
was a high stent fracture rate of 32% despite pre-stenting [66].
Boudjemline et al [67] showed that for patients with large
RVOT, multiple stenting in Russian-doll style or jailing the
PA method can create a suitable landing zone for the trans-
catheter valve (Fig. 8). Off-label use of the larger-diameter 29-
mm Sapien XT and S3 valves in large native RVOT is being
performed in select patients, and newer valves are being de-
veloped specifically for that indication [68].
The timing of pulmonary valve replacement in asymptom-
atic patients remains somewhat controversial [17, 25, 52, 53].
The advent of transcatheter valve therapies is in reality
Fig. 2 a Antero-posterior (AP) angiographic view of a bioprosthetic
pulmonary valve (BPV) with contrast injection in the pulmonary artery
showing severe pulmonary regurgitation and a stent in the right
pulmonary artery. b AP view of the same bioprosthetic valve after
transcatheter pulmonary valve placement (TPV) of a Melody valve. No
residual pulmonary regurgitation is seen
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lowering the threshold for pulmonary valve replacement.
Some experts argue that all patients with severe pulmonary
regurgitation should undergo pulmonary valve replacement
prior to the development of right ventricular dilation or dys-
function [17]. This aggressive early intervention approach
must be weighed against the procedural risks, the potential
for infective endocarditis, and the potential decrease in the
internal orifice diameter of surgically placed conduits or
bioprosthetic valves with multiple transcatheter pulmonary
valve implants over a patient’s lifetime [16].
Fig. 3 a Antero-posterior and cranial projection of a contrast injection
into the main pulmonary artery (MPA) demonstrating severe pulmonary
regurgitation into the native right ventricular outflow tract (RVOT). The
right and left pulmonary arteries (RPA and LPA) are labeled, with a
narrowing just proximal to the branching of the MPA measuring
approximately 14.9 mm. Note sternal wires from previous median
sternotomy. b Bare metal stent placed across the narrowed MPA. c
Image following Melody transcatheter pulmonary valve (TPV)
placement within the stent. Contrast injection in the MPA shows no
residual pulmonary regurgitation
Fig. 4 a Lateral angiographic view of a native right ventricular outflow
tract (RVOT) with a wire placed in the distal left pulmonary artery and
catheter in a dilated main pulmonary artery (MPA) showing severe
regurgitation across a dysfunctional native pulmonary valve (PV). b
Antero-posterior (AP) angiographic view of the same native RVOT
showing severe PR. c AP fluoroscopic view of the Sapien XT
transcatheter pulmonary valve (TPV) positioned within a stent across
the native pulmonary valve. d Lateral view of the Sapien valve delivery
system positioned across the pre-stented PV. e AP view of deployed
Sapien valve within the stented PV. f Lateral view of the deployed
Sapien valve within the pre-stented PV
Fig. 5 a Antero-posterior (AP) view of a fractured Melody transcatheter
pulmonary valve (TPV) within a right ventricular to pulmonary artery
homograft. b AP view of a deployed Melody TPV within the
previously fractured Melody valve after pre-stenting. c Transthoracic
echocardiographic image with continuous wave (CW) Doppler across
the fractured Melody TPV demonstrating moderate stenosis (peak
velocity 3.6 m/s, peak gradient of 53 mmHg, and mean gradient
29 mmHg). d Transthoracic echocardiographic image with CW
Doppler signal across the deployed Melody valve within the previously
fractured Melody valve showing significant improvement (reduction in
velocity to 2.3 m/s, peak gradient to 22 mmHg and mean gradient to
14 mmHg)
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Tricuspid Valve
In congenital heart disease patients, prior surgical repair often
involves annuloplasty rings with tricuspid valve repair, and
less often tricuspid valve replacement. The risk of recurrent
regurgitation in tricuspid valve repair is high and many will
eventually require valve replacement [69]. Bioprosthetic TVR
is associated with valvular stenosis and/or regurgitation as a
long-term consequence [26, 27]. Transcatheter tricuspid valve
replacement is feasible, and there is a growing body of evi-
dence for the use of both the Melody and Sapien valves in
failing tricuspid valve rings or bioprostheses (Figs. 9 and 10).
The procedural success rate is high and immediate hemody-
namic benefits are evident (Fig. 11); however, there is paucity
of intermediate and long-term data [70–84]. The large-
diameter Sapien valves have been successfully utilized in tri-
cuspid annuloplasty rings and bands; however, the experience
is limited to isolated case reports [80].
In native valves, theMitraClip (Evalve) has been used from
a transjugular approach; however, the tricuspid valve mor-
phology (three leaflets and chordal attachments to the right
ventricular wall) makes it more difficult to successfully posi-
tion the Mitraclip [60]. Other devices used include the
Mitralign (Mitralign), a device originally designed to remodel
the mitral annulus using pledgeted sutures, which has been
successfully placed in some patients with severe tricuspid re-
gurgitation [85]. The TriCinch (4Tech) [86], a percutaneous
Fig. 6 Antero-posterior (AP) angiographic view of aortic root injection
with simultaneous balloon inflation across the RVOT showing coronary
artery compression (black arrow) of an anomalous left anterior
descending artery
Fig. 7 aAntero-posterior (AP) angiographic view of aortic root injection
prior to balloon inflation within a dysfunctional bioprosthetic pulmonary
valve. b Aortic root injection with simultaneous balloon inflation across
the pulmonary valve showing aortic root compression and the
development of aortic regurgitation (black arrow)
Fig. 8 a Antero-posterior (AP) and cranial (CRA) angiographic view of
a patient with transannular patch repair of the right ventricular outflow
tract (RVOT) and main pulmonary artery (MPA) with a relative
narrowing (black arrow) proximal to the bifurcation. The right ventricle
(RV) is severely dilated. Right pulmonary arteries = RPA; left pulmonary
artery = LPA. b Following pre-stenting with two stents, one extending
into the LPA and Bjailing^ the RPA, but with open stent struts allowing
antegrade bloodflow into the RPA. The Sapien transcatheter pulmonary
valve (TPV) placement was deployed within the two stents. This
technique allows for anchoring of the TPV in dilated RVOTs. Contrast
injection in the LPA demonstrates a competent TPV without significant
pulmonary regurgitation
Fig. 9 a Right anterior oblique (RAO) angiographic view of an inflated
30-mm balloon across a previously surgically placed incomplete tricuspid
valve ring (white arrow). Simultaneous selective right coronary artery
injection shows no evidence of compression. b Sapien transcatheter
valve replacement (TVR) within the ring. c Transthoracic
echocardiographic image (apical four-chamber view) with color
Doppler flow showing severe tricuspid regurgitation across the native
tricuspid valve. d Transthoracic echocardiographic image (apical four-
chamber view) with color Doppler flow showing mild regurgitation
across the Sapien valve
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device designed for annular cinching of the tricuspid annulus,
and the Millipede (Millipede), which involves the transcuta-
neous placement of a tricuspid annular ring with an attach-
ment system, are still in pre-clinical trials.
Caval transcatheter valve implantation is another potential
treatment option for severe tricuspid valve regurgitation,
where valves are implanted in the superior and inferior vena
cavae, with several case reports demonstrating hemodynamic
success [83, 87, 88]. Clinical trials are currently investigating
Sapien XT implantation in the inferior vena cava in patients
with severe tricuspid regurgitation at prohibitive surgical risk
(HOVER Clinical Trial NCT02339974, and TRICAVAL
Clinical Trial NCT02387697).
Conclusions
Right-sided transcatheter valvular implantation in pa-
tients with congenital heart disease and conduit or
bioprosthetic valve dysfunction is not only gaining mo-
mentum with enormous potential for growth and inno-
vation but is also quickly becoming the new standard of
care. The minimally invasive and effective techniques of
transcatheter valvular implantation have allowed for a
reduction in the number of open cardiac surgeries that
a patient with CHD can anticipate undergoing over a
lifetime, therefore affecting the morbidity of this grow-
ing patient population. The use of TCPV in native
RVOT is increasing, especially with the advent of
large-diameter TCPV. There is a growing body of data
on the efficacy and safety of transcatheter valve inter-
ventions in patients with tricuspid valve dysfunction.
Pre-procedural planning with the use of multiple imag-
ing modalities is integral to procedural success, and it is
critical to combine both structural and functional data
for determining the correct timing of any intervention.
An interdisciplinary team approach is most ideal, with
incorporation of hybrid procedures using both surgical
and catheter-based techniques. A larger body of evi-
dence with intermediate and long-term outcomes is
needed to assess the longevity of these new techniques
in comparison to the current surgical gold standard.
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Fig. 10 a Right anterior oblique (RAO) angiographic view of an inflated
30-mm Nucleus balloon (NuMED) across the surgically placed
dysfunctional bioprosthetic Mosaic valve (Medtronic) in the tricuspid
position. Simultaneous selective right coronary artery injection shows
no evidence of compression. b Sapien valve being positioned across the
bioprosthetic Mosaic valve. c RAO angiographic view of the deployed
Sapien transcatheter valve in the tricuspid position. d Lateral
angiographic view of the deployed Sapien valve in the tricuspid position
Fig. 11 a Invasive hemodynamic tracings of simultaneous right
ventricular and right atrial pressures in a patient with atrial fibrillation
and a stenotic bioprosthetic tricuspid valve showing elevated diastolic
gradients (shaded black area)—mean gradient 8 mmHg. b Invasive
hemodynamic tracings of right ventricular and right atrial pressures
showing reduction of tricuspid stenosis to the mild range (mean
gradient 3 mmHg) after transcutaneous valve placement. c
Transthoracic echocardiographic image with CW Doppler across the
tricuspid valve showing moderate stenosis (mean gradient 7 mmHg). d
Transthoracic echocardiographic image with CW Doppler across the
tricuspid valve demonstrating reduction of mean gradient to 3 mmHg
after transcutaneous valve placement
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